Skip to main content
Fig. 6 | Journal of Nanobiotechnology

Fig. 6

From: A novel microglia-targeting strategy based on nanoparticle-mediated delivery of miR-26a-5p for long-lasting analgesia in chronic pain

Fig. 6

miR-26a-5p@A-MSN-MG1 delivery system maintains a prolonged regulation on Wnt5a signaling pathway. A–E Western blot was used to assess the level of Wnt5a (B), Ror2 (C), p-JNK (D) and NFAT (E) at day 3, 7, 14, and 21 after SNI modeling. Data are expressed as fold change compared to the sham group. F–L Western blot was used to assess the level of Wnt5a (G), Ror2 (H), p-JNK (I) and NFAT (J), iNOS (K) and CD206 (L) in different treatment groups. Representative immunoblots and quantification showing Foxy-5 reversed the effect of miR@A-MSN-MG1. Data are expressed as fold change compared to the sham group. M–P Protein levels of IL-1β (M), TNF-α (N), IL-6 (O) and IL-10 (P), in the L4–L5 dorsal spinal cord of mice after Foxy-5 reverse were tested by ELISA at day 21. N = 6 mice for each group. Data are represented as mean ± sem. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page